血府逐瘀汤治疗代偿期乙型肝炎肝硬变120例

Clinical Study of Blood Stasis Expelling Decoction for Treating 120 Cases with Decompensated Hepatitis B Cirrhosis

目的:观察血府逐瘀汤治疗代偿期乙型肝炎肝硬变的临床疗效。方法:将240例代偿期乙型肝炎肝硬变患者随机分为治疗组及对照组各120例,对照组采用内科综合治疗(抗病毒、保肝、降酶、退黄等),治疗组在对照组治疗的基础上加服血府逐瘀汤,两组均治疗1 a,分别在治疗前后以及停用血府逐瘀汤后2 a调查两组病例的生存状况,统计比较两组间的生存率,腹水、肝癌的发生率。结果:对照组3 a生存率为87.51%,治疗组3 a生存率为94.17%,两组比较差异有显著性意义(P<0.05);对照组肝硬变稳定率为78.33%,治疗组肝硬变稳定率为88.33%,两组比较差异有显著性意义(P<0.05);对照组肝癌发生率为6.67%,治疗组肝癌发生率为4.17%,两组比较差异无显著性意义(P>0.05)。结论:血府逐瘀汤可一定程度上改善代偿期乙型肝炎肝硬变患者的预后,减少肝硬变患者腹水的出现。

Objective： To observe the clinical effects of Blood Stasis Expelling Decoction for treating decompensated hepatitis B cirrhosis. Methods： 240 cases with decompensated hepatitis B cirrhosis were randomized into the treatment group（ 120 cases） and control group（ 120 cases）. The control group were treated by internal comprehensive therapy（ fighting virus,protecting the liver,decreasing enzyme and removing jaundice,etc.）; the treatment groups were given Blood Stasis Expelling Decoction additionally. Both groups were treated for 1 year. The living conditions before and after 2 years of the treatment as well as after the administration of Blood Stasis Expelling Decoction for 2 years were investigated. The survival rate and the incidence rate of ascites and liver cancer were determined and compared. Results： The survival rate of the control group was 87. 51% for the 3 years while that of the treatment group was 94. 17%. By comparison,the difference was remarkable（ P〈0. 05）; the stability rate of the hepatocirrhosis in the control group was 78. 33% while that of the treatment group was 88. 33%. By comparison,the difference was remarkable（ P〈0. 05）. The incidence rate of liver cancer of the control group was 6. 67% while that of the treatment group was4. 17. By comparison,there was no significant difference（ P〉0. 05）. Conclusion： Blood Stasis Expelling Decoction can improve the prognosis of the patients with decompensated hepatitis B cirrhosis,and reduce the occurrence of cirrhotic ascites.